“Marvin, the Paranoid Android”: The Case of an Alpha-PVP User in the Expanding Galaxy of NPS

References

• Aarde, S. M., K. M. Creehan, S. A. Vandewater, T. J. Dickerson, and M. A. Taffe. 2015. In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3, 4-methylenedioxypyrovalerone: Self-administration and locomotor stimulation in male rats. Psychopharmacology 232 (16):3045–55. doi:10.1007/s00213-015-3944-8.
   PubMed Web of Science ®Google Scholar
• Beck, O., L. Franzén, M. Bäckberg, P. Signell, and A. Helander. 2016. Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): Results from intoxication cases within the STRIDA project. Clinical Toxicology 54 (7):568–75. doi:10.1080/15563650.2016.1190979.
   PubMed Web of Science ®Google Scholar
• Bossong, M., J. Van Dijk, and R. Niesink. 2005. Methylone and mCPP, two new drugs of abuse? Addiction Biology 10 (4):321–23. doi:10.1080/13556210500350794.
   PubMed Web of Science ®Google Scholar
• Bowden-Jones, O. 2012. One year results from a UK specialist club drug clinic: Who presented and what are they using. Paper presented at the First International Conference on Novel Psychoactive Substances (NPS): The Ever-Changing World of Psychoactive Drugs, Budapest, March 12–13.
   Google Scholar
• Bowden-Jones, O. 2014a. From club to clinic: What every clinician needs to know about NPS harms and treatment. Paper presented at the Third International Conference on Novel Psychoactive Substances, Rome (15-16 May 2014).
   Google Scholar
• CannabisCafe.net. 2014. Alfa-PVP y la addiction. http://www.cannabiscafe.net/foros/showthread.php/338019-Alfa-PVP-y-la-adicci%C3%B3n.
   Google Scholar
• Carrozzino, D., O. Vassend, F. Bjørndal, C. Pignolo, L. R. Olsen, and P. Bech. 2016. A clinimetric analysis of the Hopkins Symptom Checklist (SCL-90-R) in general population studies (Denmark, Norway, and Italy). Nordic Journal of Psychiatry 70 (5):374–79. doi:10.3109/08039488.2016.1155235.
   PubMed Web of Science ®Google Scholar
• Colon-Perez, L. M., K. Tran, K. Thompson, M. C. Pace, K. Blum, B. A. Goldberger, M. S. Gold, A. W. Bruijnzeel, B. Setlow, and M. Febo. 2016. The psychoactive designer drug and bath salt constituent MDPV causes widespread disruption of brain functional connectivity. Neuropsychopharmacology 41 (9):2352–65. doi:10.1038/npp.2016.40.
   PubMed Web of Science ®Google Scholar
• Coppola, M., and R. Mondola. 2012. 3,4-Methylenedioxypyrovalerone (MDPV): Chemistry, pharmacology and toxicology of a new designer drug of abuse marketed online. Toxicology Letters 208 (1):12–15. doi:10.1016/j.toxlet.2011.10.002.
   PubMed Web of Science ®Google Scholar
• Corazza, O., S. Assi, P. Simonato, J. Corkery, Z. Demetrovics, J. Stair, S. Fergus, C. Pezzolesi, M. Pasinetti, P. Deluca, C. Drummond, Z. Davey, U. Blaszko, J. Moskalewicz, B. Mervo, L. D. Furia, M. Farre, L. Flesland, A. Pisarska, H. Shapiro, H. Siemann, A. Skutle, E. Sferrazza, M. Torrens, F. Sambola, P. Van Der Kreeft, N. Scherbaum, and F. Schifano. 2013. Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: The outcomes of the ReDNet project. Human Psychopharmacology 28 (4):317–23. doi:10.1002/hup.2299.
   PubMed Web of Science ®Google Scholar
• Corazza, O., P. Simonato, J. Corkery, G. Trincas, and F. Schifano. 2014. “Legal highs”: Safe and legal “heavens”? A study on the diffusion, knowledge and risk awareness of novel psychoactive drugs among students in the UK. Rivista di Psichiatria 49 (2):89–94.
   PubMed Web of Science ®Google Scholar
• Costa, C., A. Araujo, M. Brasil, and M. Cruz. 2014. Possible addiction transference from cocaine insufflation to oral bupropion in bipolar patient. Journal of Addiction Medicine 9:155–56. doi:10.1097/ADM.0000000000000098.
   Web of Science ®Google Scholar
• Crespi, C. 2016. Flakka-induced prolonged psychosis. Case Reports in Psychiatry 2016. http://dx.doi.org/10.1155/2016/3460849
   PubMedGoogle Scholar
• Davey, Z., F. Schifano, O. Corazza, and P. Deluca. 2012. e-Psychonauts: Conducting research in online drug forum communities. Journal of Mental Health 21 (4):386–94. doi:10.3109/09638237.2012.682265.
   PubMed Web of Science ®Google Scholar
• DEA. 2014. Schedules of controlled substances: Temporary placement of 10 synthetic cathinones into Schedule I. Final order. Federal Register 79:12938–43.
   PubMedGoogle Scholar
• Di Forti, M., C. Morgan, P. Dazzan, C. Pariante, V. Mondelli, T. R. Marques, R. Handley, S. Luzi, M. Russo, A. Paparelli, A. Butt, S. A. Stilo, B. Wiffen, J. Powell, and R. M. Murray. 2009. High-potency cannabis and the risk of psychosis. Biological Psychiatry 72:811–16. doi:10.1016/j.biopsych.2012.06.020.
   Web of Science ®Google Scholar
• Drugsforum.com. 2012–2016. Threads tagged with Alpha-PVP. https://drugs-forum.com/forum/tags.php?tag=alpha-pvp.
   Google Scholar
• Dumestre-Toulet, V., S. Brault, and F. Penouil-Pucheu. 2016. Cathinones de synthèse: 2 nouveaux cas d’intoxications au Flakka (α-PVP). Toxicologie Analytique et Clinique 28 (2):S29. doi:10.1016/j.toxac.2016.03.047.
   Google Scholar
• Dunne, F. J., K. Jaffar, and S. Hashmi. 2015. Legal highs: Not so new and still growing in popularity. British Journal of Medical Practitioners 8 (1):25–34.
   Google Scholar
• Erowid.org. 2013. A completely misunderstood compound: An experience with Alpha-PVP (ID 99718). https://www.erowid.org/experiences/exp.php?ID=99718.
   Google Scholar
• Erowid.org. 2015. Erowid.org: Alpha-PVP. https://erowid.org/chemicals/a-pvp/a-pvp.shtml.
   Google Scholar
• European Monitoring Centre for Drugs and Drugs Addiction, EMCDDA. 2007. European Drug Report 2007: The state of the drugs problem in Europe. Lisbon.
   Google Scholar
• European Monitoring Centre for Drugs and Drugs Addiction, EMCDDA. 2011. First international multidisciplinary forum on new drugs. Lisbon, Portugal: EMCDDA.
   Google Scholar
• European Monitoring Centre for Drugs and Drugs Addiction, EMCDDA. 2014. European Drug Report 2014: Trends and developments. Lisbon, Portugal: EMCDDA.
   Google Scholar
• European Monitoring Centre for Drugs and Drugs Addiction, EMCDDA. 2015a. The Internet and drug markets: SORFAET study. Lisbon.
   Google Scholar
• European Monitoring Centre for Drugs and Drugs Addiction, EMCDDA. 2015b. α-PVP Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP) in the framework of the council decision on new psychoactive substances. Lisbon.
   Google Scholar
• European Monitoring Centre for Drugs and Drugs Addiction, EMCDDA-Europol. 2015. Joint report on a new psychoactive substance: 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (α-PVP). Lisbon.
   Google Scholar
• Farré, M., C. Perez-Maña, E. De Souza, J. Mateus, E. Theunisen, K. Kuypers, J. Ramaekers, F. Fonseca, M. Torrens, and E. Olesti. 2016. Interactions between mephedrone and alcohol in humans: Cardiovascular and subjective effects. European Psychiatry 33:S115. doi:10.1016/j.eurpsy.2016.01.122.
   Google Scholar
• German, C. L., A. E. Fleckenstein, and G. R. Hanson. 2014. Bath salts and synthetic cathinones: An emerging designer drug phenomenon. Life Sciences 97 (1):2–8. doi:10.1016/j.lfs.2013.07.023.
   PubMed Web of Science ®Google Scholar
• Graham, J. R. 1990. MMPI-2: Assessing personality and psychopathology. New York, NY: Oxford University Press.
   Google Scholar
• Greene, R. L. 2000. The MMPI-2: An interpretive manual. Allyn & Bacon. Needham Heights.
   Google Scholar
• Grifell, M., P. Quintana, M. Torrens, A. Palma, L. Galindo, M. Ventura, I. Fornís, C. Gil, F. Caudevilla, and M. Farré. 2016. “Flakka”: An emerging trend or a mass media phenomenon? Presence of Alpha-PVP in samples submitted to a drug checking facility. European Psychiatry 33:S442. doi:10.1016/j.eurpsy.2016.01.1609.
   Google Scholar
• Hall, W., and L. Degenhardt. 2015. High potency cannabis. BMJ 350:1205. doi:10.1136/bmj.h1205.
   PubMed Web of Science ®Google Scholar
• Hockenhull, J., K. G. Murphy, and S. Paterson. 2016. Mephedrone use is increasing in London. The Lancet 387 (10029):1719–20. doi:10.1016/S0140-6736(16)30258-6.
   PubMed Web of Science ®Google Scholar
• Kaizaki, A., S. Tanaka, and S. Numazawa. 2014. New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (Alpha-PVP) activates central nervous system via dopaminergic neuron. The Journal of Toxicological Sciences 39 (1):1–6. doi:10.2131/jts.39.1.
   PubMed Web of Science ®Google Scholar
• Katselou, M., I. Papoutsis, P. Nikolaou, C. Spiliopoulou, and S. Athanaselis. 2016. α-PVP (“flakka”): A new synthetic cathinone invades the drug arena. Forensic Toxicology 34 (1):41–50. doi:10.1007/s11419-015-0298-1.
   Web of Science ®Google Scholar
• Kelly, J. P. 2011. Cathinone derivatives: A review of their chemistry, pharmacology and toxicology. Drug Testing and Analysis 3 (7–8):439–53. doi:10.1002/dta.313.
   PubMed Web of Science ®Google Scholar
• Klavž, J., M. Gorenjak, and M. Marinšek. 2016. Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC. Forensic Science International 265:121–24. doi:10.1016/j.forsciint.2016.01.018.
   PubMed Web of Science ®Google Scholar
• Knoy, J. L., B. L. Peterson, and F. J. Couper. 2014. Suspected impaired driving case involving α-pyrrolidinovalerophenone, methylone and ethylone. Journal of Analytical Toxicology 38 (8):615–17. doi:10.1093/jat/bku073.
   PubMed Web of Science ®Google Scholar
• Kolanos, R., F. Sakloth, A. D. Jain, J. S. Partilla, M. H. Baumann, and R. A. Glennon. 2015. Structural modification of the designer stimulant α-Pyrrolidinovalerophenone (α-PVP) influences potency at dopamine transporters. ACS Chemical Neuroscience 6 (10):1726–31. doi:10.1021/acschemneuro.5b00160.
   PubMed Web of Science ®Google Scholar
• Martinotti, G., M. Lupi, T. Acciavatti, E. Cinosi, R. Santacroce, M. S. Signorelli, L. Bandini, G. Lisi, D. Quattrone, P. Ciambrone, A. Aguglia, F. Pinna, S. Cal, L. Janiri, and M. Di Giannantonio. 2014. Novel psychoactive substances in young adults with and without psychiatric comorbidities. BioMed Research International 2014:815424. doi:10.1155/2014/815424.
   PubMed Web of Science ®Google Scholar
• Marusich, J. A., T. W. Lefever, B. E. Blough, B. F. Thomas, and J. L. Wiley. 2016. Pharmacological effects of methamphetamine and alpha-PVP vapor and injection. Neurotoxicology 55:83–91. doi:10.1016/j.neuro.2016.05.015.
   PubMed Web of Science ®Google Scholar
• Mooney, R., P. Simonato, R. Ruparelia, A. Roman-Urrestarazu, G. Martinotti, and O. Corazza. 2017. The use of supplements and performance and image enhancing drugs in fitness settings: An explorative cross-sectional investigation in the United Kingdom. Human Psychopharmacology: Clinical and Experimental. Special Issue on Novel Psychoactive Substances, 32 (3): e2619.
   Google Scholar
• Negreira, N., C. Erratico, T. Kosjek, A. L. Van Nuijs, E. Heath, H. Neels, and A. Covaci. 2015. In vitro Phase I and Phase II metabolism of α-pyrrolidinovalerophenone (α-PVP), methylenedioxypyrovalerone (MDPV) and methedrone by human liver microsomes and human liver cytosol. Analytical and Bioanalytical Chemistry 407 (19):5803–16. doi:10.1007/s00216-015-8763-6.
   PubMed Web of Science ®Google Scholar
• Novel Psychoactive Treatment UK Network, NEPTUNE. 2015. Guidance on the clinical management of acute and chronic harms of club drugs and novel psychoactive substances. The Health Foundation Inspiring Improvement. The Health Foundation. London, United Kingdom.
   Google Scholar
• O’Byrne, P. M., R. Williams, J. J. Walsh, and J. F. Gilmer. 2014. Synthesis, screening and pharmacokinetic evaluation of potential prodrugs of bupropion, part one: In vitro development. Pharmaceuticals 7 (5):595–620. doi:10.3390/ph7050595.
   Google Scholar
• Oppek, K., G. Koller, A. Zwergal, and O. Pogarell. 2014. Intravenous administration and abuse of bupropion: A case report and a review of the literature. Journal of Addiction Medicine 8 (4):290–93. doi:10.1097/ADM.0000000000000044.
   PubMed Web of Science ®Google Scholar
• Orsolini, L., G. D. Papanti, G. Francesconi, and F. Schifano. 2015. Mind navigators of chemicals’ experimenters? A web-based description of E-psychonauts. Cyberpsychology, Behavior, and Social Networking 18 (5):296–300. doi:10.1089/cyber.2014.0486.
   PubMed Web of Science ®Google Scholar
• Parrott, A. C., C. Montgomery, M. A. Wetherell, L. A. Downey, C. Stough, and A. B. Scholey. 2014. MDMA, cortisol, and heightened stress in recreational ecstasy users. Behav Pharmacol 25 (5–6):458–72.
   PubMed Web of Science ®Google Scholar
• Prosser, J., and L. Nelson. 2012. The toxicology of bath salts: A review of synthetic cathinones. Journal of Medical Toxicology 8 (1):33–42. doi:10.1007/s13181-011-0193-z.
   PubMedGoogle Scholar
• Psychonaut.com. 2013. Alpha-PVP. http://www.psychonaut.com/esperienze/51680-alpha-pvp.html
   Google Scholar
• Psyvault.net. 2011. Alfa PVP. http://psyvault.net/viewtopic.php?t=4508&f=3.
   Google Scholar
• Reddit.com. 2014. RCs to increase sex drive? https://www.reddit.com/r/Drugs/comments/1zzs5p/rcs_to_increase_sex_drive/.
   Google Scholar
• Rouse, S., J. N. Butcher, and K. B. Miller. 1999. Assessment of substance abuse in psychotherapy clients: The effectiveness of the MMPI-2 substance abuse scales. Psychological Assessment 11 (1):101–07. doi:10.1037/1040-3590.11.1.101.
   Web of Science ®Google Scholar
• Sauer, C., F. T. Peters, C. Haas, M. R. Meyer, G. Fritschi, and H. H. Maurer. 2009. New designer drug α‐pyrrolidinovalerophenone (PVP): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. Journal of Mass Spectrometry 44 (6):952–64. doi:10.1002/jms.1571.
   PubMed Web of Science ®Google Scholar
• Sawrie, S., M. H. Kabat, C. B. Dietz, R. L. Greene, R. Arredondo, and A. W. Mann. 1996. Internal structure of the MMPI-2 addiction potential scale in alcoholic and psychiatric inpatients. Journal of Personality Assessment 66 (1):177–93. doi:10.1207/s15327752jpa6601_14.
   PubMed Web of Science ®Google Scholar
• Schifano, F., A. Albanese, S. Fergus, J. L. Stair, P. Deluca, O. Corazza, Z. Davey, J. Corkery, H. Siemann, N. Scherbaum, M. Farre’, M. Torrens, Z. Demetrovics, and A. H. Ghodse. 2011. Mephedrone (4-methylmethcathinone; “meow meow”): Chemical, pharmacological and clinical issues. Psychopharmacology 214 (3):593–602. doi:10.1007/s00213-010-2070-x.
   PubMed Web of Science ®Google Scholar
• Schifano, F., L. Orsolini, D. Papanti, and J. M. Corkery. 2015. Novel psychoactive substances of interest for psychiatry. World Psychiatry 14 (1):15–26. doi:10.1002/wps.20174.
   PubMed Web of Science ®Google Scholar
• Sedefov, R., and A. Gallegos. 2011. Risks assessments: Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances. EMCDDA. Lisbon.
   Google Scholar
• Simonato, P., O. Corazza, P. Santonastaso, J. Corkery, P. Deluca, Z. Davey, U. Blaszko, and F. Schifano. 2013. Novel psychoactive substances as a novel challenge for health professionals: Results from an Italian survey. Human Psychopharmacology 28 (4):324–31. doi:10.1002/hup.2300.
   PubMed Web of Science ®Google Scholar
• Smith, D., S. Negus, B. Blough, and M. Banks. 2016. Cocaine-like discriminative stimulus effects of amphetamine, cathinone, and alpha-pyrrolidinovalerophenone analogs in male rhesus monkeys. The FASE B Journal 30 (1 Supplement):1183–84.
   Google Scholar
• Steinberg, J. 2015. Flakka: The new illegal drug you need to know about. http://www.inc.com/joseph-steinberg/flakka-the-new-illegal-drug-you-need-to-know-about.html.
   Google Scholar
• Umebachi, R., H. Aoki, M. Sugita, T. Taira, S. Wakai, T. Saito, and S. Inokuchi. 2016. Clinical characteristics of α-pyrrolidinovalerophenone (α-PVP) poisoning. Clinical Toxicology 54 (7):563–67. doi:10.3109/15563650.2016.1166508.
   PubMed Web of Science ®Google Scholar
• United Nations Office on Drugs and Crime, UNODC. 2013. The challenge of new psychoactive substances: A report from the Global SMART Programme. Vienna, Austria.
   Google Scholar
• United Nations Office on Drugs and Crime, UNODC. 2016. Global SMART Update 2016.
   Google Scholar
• Winstock, A., L. Mitcheson, and J. Marsden. 2010. Mephedrone: Still available and twice the price. The Lancet 376 (9752):1537. doi:10.1016/S0140-6736(10)62021-1.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2015. Expert committee on drug dependence, thirty-seventh meeting: 1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-PVP). Critical Review Report Agenda item 5.3. Geneva, Switzerland: WHO.
   Google Scholar
• Wright, T. H., and C. Harris. 2016. Twenty-one cases involving alpha-pyrrolidinovalerophenone (α-PVP). Journal of Analytical Toxicology 40 (5):396–402. doi:10.1093/jat/bkw029.
   PubMed Web of Science ®Google Scholar